Spyglass Pharma (NASDAQ:SGP – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright‘s price objective would suggest a potential upside of 32.19% from the company’s current price.
SGP has been the subject of several other reports. Raymond James Financial started coverage on shares of Spyglass Pharma in a research note on Friday, August 14th. They issued an “outperform” rating and a $39.00 target price for the company. UBS Group reissued a “buy” rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Wall Street Zen cut shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings cut shares of Spyglass Pharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, September 25th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.
View Our Latest Stock Analysis on Spyglass Pharma
Spyglass Pharma Stock Down 0.8%
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11). As a group, equities analysts predict that Spyglass Pharma will post -2.55 earnings per share for the current year.
Institutional Investors Weigh In On Spyglass Pharma
Several hedge funds have recently added to or reduced their stakes in SGP. Bank of New York Mellon Corp acquired a new stake in shares of Spyglass Pharma during the second quarter worth $533,000. Bank of America Corp DE acquired a new stake in shares of Spyglass Pharma during the first quarter worth $726,000. Affinity Asset Advisors LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth $6,478,000. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth $9,716,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth $2,461,000.
Spyglass Pharma Company Profile
SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.
SpyGlass Pharma’s lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.
The company is advancing its technology through clinical development and regulatory processes in the United States.
Recommended Stories
- Five stocks we like better than Spyglass Pharma
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
